D-lactic acid dimer local application for selective cancer cell cytotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering D-lactic acid dimer systemically are unlikely to achieve effective concentrations due to toxicity concerns, and its cytotoxic effects are obscured by pH changes, limiting its potential as a cancer treatment.
Innovation Solution
Local application of D-lactic acid dimer directly onto or into tumors, which forms a stereocomplex with L-lactate to sequester it, demonstrating cytotoxicity independent of pH changes, thereby targeting cancer cells that rely on glycolysis for ATP production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If D-lactic acid dimer is administered systemically (oral or parenteral route), then it can potentially treat cancer cells throughout the body, but the concentration required to form the stereocomplex is not realistically obtainable due to toxicity concerns
Solution Approach 1:
The patent transitions from systemic administration to local application of D-lactic acid dimer directly onto or into tumors. This local quality principle allows achieving high effective concentrations at the tumor site without exposing the entire body to toxic levels systemically. The drug is concentrated where needed (in the tumor) while minimizing harmful effects elsewhere in the body.
2Reliability
If D-lactic acid dimer is applied to cancer cells, then it sequesters L-lactate and kills cancer cells, but the cytotoxic effects are obscured by pH changes
Solution Approach 1:
The patent extracts and isolates the specific cytotoxic mechanism of D-lactic acid dimer from the confounding pH effects. By controlling and accounting for pH changes separately, the researchers were able to demonstrate that the stereocomplex formation and L-lactate sequestration are distinct from pH-mediated cytotoxicity. This allows reliable attribution of cancer cell death to the primary mechanism of action.
3Productivity
If high concentration of D-lactic acid dimer is used to achieve effective cytotoxicity, then cancer cells are killed, but normal cells may also be affected
Solution Approach 1:
The patent applies D-lactic acid dimer locally to tumors rather than systemically, creating a high concentration gradient that is tumoricidal at the application site while maintaining safety for surrounding normal tissues. The local application ensures that normal cells are exposed to sub-toxic concentrations, preserving their function while eliminating cancer cells.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The local application of D-lactic acid dimer effectively kills cancer cells, including HeLa and retinoblastoma cells, with cytotoxic effects observed at specific concentrations, while being less cytotoxic to normal cells, supporting its potential as a tumoricidal agent.
Implementation Method 1
a stereocomplex chemical reaction occurred between L-lactate and Polymer D-lactic acid (PDLA). A stereocomplex is a new substance that is formed when a molecule and its mirror image (D and L or enantiomers) come together with the proper orientation.
Implementation Method 2
D-lactic acid dimer would 'sequester or trap' L-lactate
Data Source
AI summary
At equimolar concentrations, D-lactic acid dimer is more cytotoxic than L-lactic acid when directly applied to human HeLa cells in culture. The cytotoxicity of D-lactic acid dimer is an independent effect exclusive of the lower pH when applied to cancer cells in culture. At equimolar concentrations, D-lactic acid dimer is less cytotoxic than L-lactic acid when applied to normal human fibroblasts in culture. D-lactic acid dimer is cytotoxic when applied to human retinoblastoma cells in culture in a dose-dependent fashion. The experimental data supports the cytotoxic mechanism of D-lactic acid dimer via the Warburg effect.